Cargando…

In the quest for treating alcohol liver disease

Detalles Bibliográficos
Autores principales:	Ciocan, Dragos, Cassard, Anne-Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157451/ https://www.ncbi.nlm.nih.gov/pubmed/35636317 http://dx.doi.org/10.1016/j.ebiom.2022.104086

Ejemplares similares

Microbiota, a key player in alcoholic liver disease
por: Cassard, Anne-Marie, et al.
Publicado: (2018)

Pectin in Metabolic Liver Disease
por: Hu, Wanchao, et al.
Publicado: (2022)

Characterization of intestinal microbiota in alcoholic patients with and without alcoholic hepatitis or chronic alcoholic pancreatitis
por: Ciocan, Dragos, et al.
Publicado: (2018)

The quest for the “HOIL-1” grail of T-cell development
por: Alves, Nuno L., et al.
Publicado: (2021)

Modulation of the Bile Acid Enterohepatic Cycle by Intestinal Microbiota Alleviates Alcohol Liver Disease
por: Ciocan, Dragos, et al.
Publicado: (2022)

Gut Microbiota Reshaped by Pectin Treatment Improves Liver Steatosis in Obese Mice
por: Houron, Camille, et al.
Publicado: (2021)

Metabolic dysfunction-associated fatty liver disease reflects a significantly higher risk of hypertension than non-alcoholic fatty liver disease
por: Uehara, Tatsuki, et al.
Publicado: (2023)

Bile acid-receptor TGR5 deficiency worsens liver injury in alcohol-fed mice by inducing intestinal microbiota dysbiosis
por: Spatz, Madeleine, et al.
Publicado: (2021)

The quest for lower alcoholic wines
por: Caballero, Antonio, et al.
Publicado: (2017)

Patterns of drinking and disease-free living: Only a problem for alcohol abusers?
por: Rehm, Jürgen
Publicado: (2022)

Activation of Kupffer Cells Is Associated with a Specific Dysbiosis Induced by Fructose or High Fat Diet in Mice
por: Ferrere, Gladys, et al.
Publicado: (2016)

COVID-19 and liver disease: where are we now?
por: Russo, Francesco Paolo, et al.
Publicado: (2022)

Technological Innovation in Outpatient Assistance for Chronic Liver Disease and Liver Transplant Patients During the Coronavirus Disease Outbreak: A Method to Minimize Transmission
por: Ono, Suzane Kioko, et al.
Publicado: (2020)

Should UK Pneumococcal Vaccine Eligibility Criteria Include Alcohol Dependency in Areas with High Alcohol-Related Mortality?
por: Mooney, John D., et al.
Publicado: (2018)

Gene therapy to treat inherited and complex retinal degenerative diseases
por: Rex, Tonia S
Publicado: (2015)

Transplantation of human microbiota into conventional mice durably reshapes the gut microbiota
por: Wrzosek, Laura, et al.
Publicado: (2018)

Integrating social nutrition principles into the treatment of steatotic liver disease
por: Ivancovsky-Wajcman, Dana, et al.
Publicado: (2023)

Alcohol-related harms and the certainty of deaths and taxes
por: Bhala, Neeraj B.
Publicado: (2022)

Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic
por: Dougados, Maxime
Publicado: (2021)

Health and cancer risks associated with low levels of alcohol consumption
por: Anderson, Benjamin O, et al.
Publicado: (2023)

Why Treat Insomnia?
por: Perlis, Michael L., et al.
Publicado: (2021)

How can we get sober from the influence of the alcohol industry?
por: Monteiro, Maristela G, et al.
Publicado: (2022)

SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question
por: Marjot, Thomas, et al.
Publicado: (2021)

AIMing 2 treat atherosclerosis
por: Soehnlein, Oliver, et al.
Publicado: (2022)

Non-Alcoholic Fatty Liver Disease, a Marker of Subclinical Atherosclerosis Applicable Only to Metabolic Syndrome?: Time to Organize the Connection between Metabolism and Atherosclerosis
por: Lee, Seung-Pyo
Publicado: (2012)

Alcohol oxidation as alternative anode reactions paired with (photo)electrochemical fuel production reactions
por: Bender, Michael T., et al.
Publicado: (2020)

COVID-19 and liver transplantation
por: Di Maira, Tommaso, et al.
Publicado: (2020)

Are we over-treating with checkpoint inhibitors?
por: Danson, Sarah, et al.
Publicado: (2019)

Concurrent miR-21 suppression and FXR activation as a mechanism of improvement in nonalcoholic fatty liver disease
por: Mazzini, Guilherme S., et al.
Publicado: (2018)

Exploiting lipotoxicity for the treatment of liver cancer
por: Rudalska, Ramona, et al.
Publicado: (2021)

Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab
por: Felten, Renaud, et al.
Publicado: (2022)

Comment to “Recurrent Glioblastoma Treated with Recombinant Poliovirus”
por: Wang, Peng, et al.
Publicado: (2018)

US elections: treating the acute-on-chronic decompensation
por: Tsai, Alexander C, et al.
Publicado: (2020)

Treating MERS-CoV during an outbreak
por: Coleman, Christopher M, et al.
Publicado: (2014)

COVID-19 and the liver-related deaths to come
por: Pawlotsky, Jean-Michel
Publicado: (2020)

Liver injury in COVID-19: management and challenges
por: Zhang, Chao, et al.
Publicado: (2020)

Treating COVID-19-related breathlessness with novel interventions
por: Daynes, Enya
Publicado: (2022)

Targeting METTL14 and RNA methylation to treat osteosarcoma
por: Ren, Lili, et al.
Publicado: (2022)

Can community pharmacists treat hepatitis C virus?
por: Wade, Amanda J
Publicado: (2020)

Could Pirfenidone Also be Effective in Treating Intestinal Fibrosis?
por: Latella, Giovanni, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m0b4qvfulnkintpm3fo54lrp83